Fig. 6.

TC3.6 and VP 1.15 do not affect OPC proliferation but favor OPC survival at P15. a Quantification of BrdU incorporation by double immunocytochemistry in P15 OPCs characterized with the oligodendroglial marker Olig2. Like at P0, the presence of TC3.6, VP1.15, or BRL (1 μM) did not modify the number of BrdU⁺/Olig2⁺ OPCs after 3DIV versus the total number of oligodendrocytes (Olig2⁺). b Determination of dead OPCs percentage (active caspase 3⁺/A2B5⁺) versus the total number of OPCs (A2B5⁺) after 2 DIV. OPC survival increased in the presence of PDE7 inhibitors (1 μM). c Estimation of p-ERK/ERK quotient by measurement of fluorescence intensity in purified P15 OPCs cultures by immunostaining with anti-pERK and anti-ERK. p-ERK/ERK was equally activated in these cells when exposed to BRL, TC3.6, and VP 1.15 (30 μM). Values are given as mean ± SEM and the results of Student’s t test are represented as *p < 0.05, **p < 0.01, and ***p < 0.001